Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures (2024 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $113785.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 249.59% to $113785.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $113785.0, a 249.59% increase, with the full-year FY2024 number at $52884.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $113785.0 for Q3 2025 at 4D Molecular Therapeutics, up from $70278.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $113785.0 in Q3 2025 to a low of $10996.0 in Q1 2024.